MRNA analyst estimates
Moderna (MRNA) analyst ratings, the average price target and its range, and every firm's latest call.
MRNA analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 26, 2026 | Piper Sandler | Moderna price target raised to $230 from $167 at Piper Sandler | $230.00 |
| Oct 15, 2026 | Goldman Sachs | Moderna price target raised to $137 from $120 at Goldman Sachs | $137.00 |
| Sep 3, 2026 | UBS | Moderna downgraded to Sell from Neutral at Rothschild & Co Redburn | $81.00 |
| Aug 28, 2026 | Argus Research | Argus Upgrades Moderna (MRNA) to Buy | $180.00 |
| Aug 24, 2026 | Barclays | Moderna price target raised to $125 from $48 at Barclays | $125.00 |
| Aug 20, 2026 | UBS | Moderna price target raised to $150 from $50 at UBS | $150.00 |
| Aug 19, 2026 | D.A. Davidson | DA Davidson Reiterates Neutral Rating on Lowe's (LOW) as Guidance Lowered | $245.00 |
| Aug 19, 2026 | Loop Capital Markets | Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA) Following Positive Intismeran Data | $135.00 |
| Aug 19, 2026 | RBC Capital | Moderna price target raised to $130 from $45 at RBC Capital | $130.00 |
| Aug 19, 2026 | Goldman Sachs | Moderna price target raised to $120 from $67 at Goldman Sachs | $120.00 |
| Jul 21, 2026 | Goldman Sachs | Moderna price target raised to $67 from $49 at Goldman Sachs | $67.00 |
| Jul 20, 2026 | Wolfe Research | Moderna (MRNA) PT Raised to $25 at Wolfe Research | $25.00 |
| Jul 8, 2026 | Morgan Stanley | Moderna price target raised to $39 from $33 at Morgan Stanley | $39.00 |
| Jul 7, 2026 | RBC Capital | Moderna price target raised to $45 from $38 at RBC Capital | $45.00 |
| Jun 26, 2026 | Piper Sandler | Moderna price target raised to $77 from $69 at Piper Sandler | $77.00 |
- 17 firms rate MRNA: 2 buy, 10 hold, 5 sell.
- The average price target is $132.70 from 10 analysts, from $25.00 to $245.00.
Updated 2026-11-02 18:27 UTC